1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models
Introduction: We aimed to evaluate the influence of 1,25-dihydroxyvitamin D (1,25(OH)2D) on metabolic dysfunction and elucidate its underlying mechanism using a rat model of polycystic ovary syndrome (PCOS).Methods: Twenty-four Sprague-Dawley rats were randomly divided into four groups: control grou...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1077014/full |
| _version_ | 1797847420414984192 |
|---|---|
| author | Xin Yuan Jianshu Yang Danlin Sun Danlin Sun Kaiming Luo Xiaohong Jiang Long Wang Shoukui Xiang Yijie Jiang Kele Ge Zhiyang Zhou Bowen Li Fei Hua |
| author_facet | Xin Yuan Jianshu Yang Danlin Sun Danlin Sun Kaiming Luo Xiaohong Jiang Long Wang Shoukui Xiang Yijie Jiang Kele Ge Zhiyang Zhou Bowen Li Fei Hua |
| author_sort | Xin Yuan |
| collection | DOAJ |
| description | Introduction: We aimed to evaluate the influence of 1,25-dihydroxyvitamin D (1,25(OH)2D) on metabolic dysfunction and elucidate its underlying mechanism using a rat model of polycystic ovary syndrome (PCOS).Methods: Twenty-four Sprague-Dawley rats were randomly divided into four groups: control group (CON, 2 ml/kg of oral 0.5% CMC), 1,25VD group (oral 0.5% CMC and 2.5 ug/kg intraperitoneal 1,25(OH)2D), PCOS group (1 mg/kg oral letrozole), PCOS+1,25VD group (1 mg/kg oral letrozole orally 2.5 ug/kg intraperitoneal 1,25(OH)2D). The treatments were administered for 8 weeks. Body weight, estrus cycle, insulin tolerance, and oral glucose tolerance of the rats in the different groups were assessed. The rats were euthanized at the 8th weeks, and plasma, ovarian, and liver samples were collected and analyzed. The hepatic lipid profile was characterized using HPLC/MRM.Results: Letrozole-induced PCOS rats exhibited increased weight, insulin resistance, postprandial glucose abnormalities, and dyslipidemia. Compared with the PCOS group rats, the PCOS+1,25VD group rats showed reduced body weight, increased sensitivity to insulin, decreased postprandial glucose, and elevated levels of high-density lipoprotein cholesterol. Moreover, abnormally increased liver concentrations of total diacylglycerol (DG) and DG species in the PCOS rats were reversed by treatment with 1,25(OH)2D. Additionally, hepatic DG and insulin sensitivity were correlated.Conclusion: 1,25(OH)2D inhibited hepatic DG accumulation and ameliorated metabolic dysfunction in PCOS rat models. |
| first_indexed | 2024-04-09T18:12:19Z |
| format | Article |
| id | doaj.art-44f042a742c3486dac62c3132ce6b438 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-09T18:12:19Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-44f042a742c3486dac62c3132ce6b4382023-04-13T15:52:14ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-04-011410.3389/fphar.2023.107701410770141,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat modelsXin Yuan0Jianshu Yang1Danlin Sun2Danlin Sun3Kaiming Luo4Xiaohong Jiang5Long Wang6Shoukui Xiang7Yijie Jiang8Kele Ge9Zhiyang Zhou10Bowen Li11Fei Hua12Department of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaHealth Management Center, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Neurosurgery, The First People’s Hospital of Changzhou, Changzhou, ChinaClinical Medical Research Center, The First People’s Hospital of Changzhou, Changzhou, ChinaDepartment of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaDepartment of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaDepartment of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaDepartment of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaDepartment of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaDepartment of Oncology, The First People’s Hospital of Changzhou, Changzhou, ChinaLipidALL Technologies Company Limited, Changzhou, ChinaLipidALL Technologies Company Limited, Changzhou, ChinaDepartment of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, ChinaIntroduction: We aimed to evaluate the influence of 1,25-dihydroxyvitamin D (1,25(OH)2D) on metabolic dysfunction and elucidate its underlying mechanism using a rat model of polycystic ovary syndrome (PCOS).Methods: Twenty-four Sprague-Dawley rats were randomly divided into four groups: control group (CON, 2 ml/kg of oral 0.5% CMC), 1,25VD group (oral 0.5% CMC and 2.5 ug/kg intraperitoneal 1,25(OH)2D), PCOS group (1 mg/kg oral letrozole), PCOS+1,25VD group (1 mg/kg oral letrozole orally 2.5 ug/kg intraperitoneal 1,25(OH)2D). The treatments were administered for 8 weeks. Body weight, estrus cycle, insulin tolerance, and oral glucose tolerance of the rats in the different groups were assessed. The rats were euthanized at the 8th weeks, and plasma, ovarian, and liver samples were collected and analyzed. The hepatic lipid profile was characterized using HPLC/MRM.Results: Letrozole-induced PCOS rats exhibited increased weight, insulin resistance, postprandial glucose abnormalities, and dyslipidemia. Compared with the PCOS group rats, the PCOS+1,25VD group rats showed reduced body weight, increased sensitivity to insulin, decreased postprandial glucose, and elevated levels of high-density lipoprotein cholesterol. Moreover, abnormally increased liver concentrations of total diacylglycerol (DG) and DG species in the PCOS rats were reversed by treatment with 1,25(OH)2D. Additionally, hepatic DG and insulin sensitivity were correlated.Conclusion: 1,25(OH)2D inhibited hepatic DG accumulation and ameliorated metabolic dysfunction in PCOS rat models.https://www.frontiersin.org/articles/10.3389/fphar.2023.1077014/fullvitamin Dpolycystic ovary syndromemetabolic dysfunctionlipidomicsdiacyglycerol |
| spellingShingle | Xin Yuan Jianshu Yang Danlin Sun Danlin Sun Kaiming Luo Xiaohong Jiang Long Wang Shoukui Xiang Yijie Jiang Kele Ge Zhiyang Zhou Bowen Li Fei Hua 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models Frontiers in Pharmacology vitamin D polycystic ovary syndrome metabolic dysfunction lipidomics diacyglycerol |
| title | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
| title_full | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
| title_fullStr | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
| title_full_unstemmed | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
| title_short | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
| title_sort | 1 25 dihydroxyvitamin d inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
| topic | vitamin D polycystic ovary syndrome metabolic dysfunction lipidomics diacyglycerol |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1077014/full |
| work_keys_str_mv | AT xinyuan 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT jianshuyang 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT danlinsun 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT danlinsun 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT kaimingluo 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT xiaohongjiang 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT longwang 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT shoukuixiang 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT yijiejiang 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT kelege 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT zhiyangzhou 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT bowenli 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT feihua 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels |